BioCentury | Jul 31, 2020
Deals

Sangamo’s latest deal brings in Novartis, includes autism

In its second neurology-focused deal of the year, and sixth with a large biopharma, Sangamo has partnered with Novartis to turn its zinc finger gene modulation technology toward neurodevelopmental disorders, such as autism and intellectual...
BioCentury | Jul 31, 2020
Finance

Gilead expects remdesivir to drive P&L rebound by year-end

Gilead bumped up its full year guidance Thursday after projecting to manufacture 2 million treatment courses of its COVID-19 antiviral remdesivir by year-end, and sell 1-1.5 million courses even as the company reported 2Q20 earnings...
BioCentury | Jul 30, 2020
Product Development

Finding immunosuppression sweet spot could be next up for COVID-19 after second IL-6 failure

A Phase III miss for a second IL-6 inhibitor in COVID-19 patients could be the death knell for the drug class in the disease. But the mortality benefit demonstrated by dexamethasone suggests a broader immunosuppressive...
BioCentury | Jul 25, 2020
Regulation

FDA makes Gilead’s Tecartus, for mantle cell lymphoma, third U.S.-approved CAR T

Kite’s Tecartus has become the third CAR T cell therapy, after Kymriah and Yescarta, to earn FDA approval. On Friday, FDA granted accelerated approval to Tecartus brexucabtagene autoleucel from the Gilead Sciences Inc. (NASDAQ:GILD) unit...
BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

Fresh off its $200 million IPO last month, Generation Bio Co. (NASDAQ:GBIO) has added Matthew Norkunas as CFO. Norkunas, who succeeds interim CFO Stephen DiPalma, was CFO of SomaLogic Inc. IQVia Holdings Inc. (NYSE:IQV) has...
BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

Among the 11 new medicines recommended for approval by EMA’s CHMP is the first antibody-drug conjugate, and most advanced BCMA-targeted agent, for multiple myeloma patients: GSK’s Blenrep belantamab mafodotin. FDA’s Oncologic Drugs Advisory Committee unanimously...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

David Meeker will become president and CEO of obesity company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) while remaining chairman, a title he’s held since 2017. He succeeds CFO Hunter Smith, who was serving as president and CEO...
BioCentury | Jul 21, 2020
Deals

With deal for Tizona, Gilead places latest bet on cancer immunosuppression

For the second time in as many months, Gilead has made a large investment in a biotech in the cancer immunosuppression area, paying $300 million up front to acquire nearly half of privately-held Tizona with...
BioCentury | Jul 17, 2020
Deals

Bischofberger revisits Gilead castoff to pad Kronos’ pipeline of transcription modulators

New biomarker data for a clinical cancer therapy discontinued by Gilead prompted Kronos President and CEO Norbert Bischofberger to close a deal with his old company to bring the IP in-house to Kronos. The acquisition...
BioCentury | Jul 15, 2020
Emerging Company Profile

Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH

With $47.6 million in new series B cash, Glympse will conduct an authorization-enabling study designed to show its synthetic biosensor can determine disease severity and track treatment response in patients with non-alcoholic steatohepatitis. The company...
Items per page:
1 - 10 of 3899
BioCentury | Jul 31, 2020
Deals

Sangamo’s latest deal brings in Novartis, includes autism

In its second neurology-focused deal of the year, and sixth with a large biopharma, Sangamo has partnered with Novartis to turn its zinc finger gene modulation technology toward neurodevelopmental disorders, such as autism and intellectual...
BioCentury | Jul 31, 2020
Finance

Gilead expects remdesivir to drive P&L rebound by year-end

Gilead bumped up its full year guidance Thursday after projecting to manufacture 2 million treatment courses of its COVID-19 antiviral remdesivir by year-end, and sell 1-1.5 million courses even as the company reported 2Q20 earnings...
BioCentury | Jul 30, 2020
Product Development

Finding immunosuppression sweet spot could be next up for COVID-19 after second IL-6 failure

A Phase III miss for a second IL-6 inhibitor in COVID-19 patients could be the death knell for the drug class in the disease. But the mortality benefit demonstrated by dexamethasone suggests a broader immunosuppressive...
BioCentury | Jul 25, 2020
Regulation

FDA makes Gilead’s Tecartus, for mantle cell lymphoma, third U.S.-approved CAR T

Kite’s Tecartus has become the third CAR T cell therapy, after Kymriah and Yescarta, to earn FDA approval. On Friday, FDA granted accelerated approval to Tecartus brexucabtagene autoleucel from the Gilead Sciences Inc. (NASDAQ:GILD) unit...
BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

Fresh off its $200 million IPO last month, Generation Bio Co. (NASDAQ:GBIO) has added Matthew Norkunas as CFO. Norkunas, who succeeds interim CFO Stephen DiPalma, was CFO of SomaLogic Inc. IQVia Holdings Inc. (NYSE:IQV) has...
BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

Among the 11 new medicines recommended for approval by EMA’s CHMP is the first antibody-drug conjugate, and most advanced BCMA-targeted agent, for multiple myeloma patients: GSK’s Blenrep belantamab mafodotin. FDA’s Oncologic Drugs Advisory Committee unanimously...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

David Meeker will become president and CEO of obesity company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) while remaining chairman, a title he’s held since 2017. He succeeds CFO Hunter Smith, who was serving as president and CEO...
BioCentury | Jul 21, 2020
Deals

With deal for Tizona, Gilead places latest bet on cancer immunosuppression

For the second time in as many months, Gilead has made a large investment in a biotech in the cancer immunosuppression area, paying $300 million up front to acquire nearly half of privately-held Tizona with...
BioCentury | Jul 17, 2020
Deals

Bischofberger revisits Gilead castoff to pad Kronos’ pipeline of transcription modulators

New biomarker data for a clinical cancer therapy discontinued by Gilead prompted Kronos President and CEO Norbert Bischofberger to close a deal with his old company to bring the IP in-house to Kronos. The acquisition...
BioCentury | Jul 15, 2020
Emerging Company Profile

Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH

With $47.6 million in new series B cash, Glympse will conduct an authorization-enabling study designed to show its synthetic biosensor can determine disease severity and track treatment response in patients with non-alcoholic steatohepatitis. The company...
Items per page:
1 - 10 of 3899